Literature DB >> 21551018

Relaxin regulates vascular wall remodeling and passive mechanical properties in mice.

Dan O Debrah1, Julianna E Debrah, Jamie L Haney, Jonathan T McGuane, Michael S Sacks, Kirk P Conrad, Sanjeev G Shroff.   

Abstract

Administration of recombinant human relaxin (rhRLX) to conscious rats increases global arterial compliance, and small renal arteries (SRA) isolated from these rats demonstrate increased passive compliance. Here we characterize relaxin-induced vascular remodeling and examine its functional relevance. SRA and external iliac arteries (EIA) were examined in rhRLX-treated (1.0 μg/h for 5 days) and relaxin knockout mice. Arterial geometric remodeling and compositional remodeling were quantified using immunohistochemical and biochemical techniques. Vascular mechanical properties were quantified using an ex vivo preparation wherein pressure-diameter data were obtained at various axial lengths. Compared with vehicle-treated mice, SRA from rhRLX-treated mice showed outward geometric remodeling (increased unstressed wall area and wall-to-lumen area ratio), increased smooth muscle cell (SMC) density, reduction in collagen-to-total protein ratio, and unchanged elastin-to-tissue dry weight ratio. Compared with wild-type mice, relaxin knockout mice exhibited the opposite pattern: decreased unstressed wall area and wall-to-lumen area ratio, decreased SMC density, and increased collagen-to-total protein ratio. Although tissue biaxial strain energy of SRA was not different between rhRLX- and vehicle-treated groups at low-to-physiological circumferential and axial strains, it was lower for the rhRLX-treated group at the highest circumferential strain. In contrast to SRA, relaxin administration was not associated with any vascular remodeling or changes in passive mechanics of EIA. Thus relaxin induces both geometric and compositional remodeling in vessel-specific manner. Relaxin-induced geometric remodeling of SRA is responsible for the increase in passive compliance under low-to-physiological levels of circumferential and axial strains, and compositional remodeling becomes functionally relevant only under high circumferential strain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21551018      PMCID: PMC3137537          DOI: 10.1152/japplphysiol.00845.2010

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  49 in total

1.  Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats.

Authors:  R E Gandley; K P Conrad; M K McLaughlin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-01       Impact factor: 3.619

2.  Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart?

Authors:  Carol Fisher; Margaret MacLean; Ian Morecroft; Alison Seed; Fiona Johnston; Christopher Hillier; John McMurray
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

3.  Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype.

Authors:  Xiao-Jun Du; Chrishan S Samuel; Xiao-Ming Gao; Ling Zhao; Laura J Parry; Geoffrey W Tregear
Journal:  Cardiovasc Res       Date:  2003-02       Impact factor: 10.787

4.  Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats.

Authors:  Jacqueline Novak; Rolando J J Ramirez; Robin E Gandley; O David Sherwood; Kirk P Conrad
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-08       Impact factor: 3.619

5.  Smooth muscle cell changes during flow-related remodeling of rat mesenteric resistance arteries.

Authors:  C L Buus; F Pourageaud; G E Fazzi; G Janssen; M J Mulvany; J G De Mey
Journal:  Circ Res       Date:  2001-07-20       Impact factor: 17.367

6.  Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo.

Authors:  E J Williams; R C Benyon; N Trim; R Hadwin; B H Grove; M J Arthur; E N Unemori; J P Iredale
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

7.  Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis.

Authors:  Chrishan S Samuel; Chongxin Zhao; Ross A D Bathgate; Courtney P Bond; Matthew D Burton; Laura J Parry; Roger J Summers; Mimi L K Tang; Edward P Amento; Geoffrey W Tregear
Journal:  FASEB J       Date:  2002-11-01       Impact factor: 5.191

8.  Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide.

Authors:  Jonathan T McGuane; Julianna E Debrah; Laura Sautina; Yagna P R Jarajapu; Jacqueline Novak; J Peter Rubin; Maria B Grant; Mark Segal; Kirk P Conrad
Journal:  Endocrinology       Date:  2011-05-10       Impact factor: 4.736

9.  Shear level influences resistance artery remodeling: wall dimensions, cell density, and eNOS expression.

Authors:  J L Tuttle; R D Nachreiner; A S Bhuller; K W Condict; B A Connors; B P Herring; M C Dalsing; J L Unthank
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-09       Impact factor: 4.733

10.  Passive biaxial mechanical response of aged human iliac arteries.

Authors:  Christian A J Schulze-Bauer; Christian Mörth; Gerhard A Holzapfel
Journal:  J Biomech Eng       Date:  2003-06       Impact factor: 2.097

View more
  16 in total

Review 1.  Effects of relaxin on arterial dilation, remodeling, and mechanical properties.

Authors:  Kirk P Conrad; Sanjeev G Shroff
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

2.  Relaxin mediates uterine artery compliance during pregnancy and increases uterine blood flow.

Authors:  Lenka A Vodstrcil; Marianne Tare; Jacqueline Novak; Nicoleta Dragomir; Rolando J Ramirez; Mary E Wlodek; Kirk P Conrad; Laura J Parry
Journal:  FASEB J       Date:  2012-06-28       Impact factor: 5.191

Review 3.  Vascular actions of relaxin: nitric oxide and beyond.

Authors:  C H Leo; M Jelinic; H H Ng; S A Marshall; J Novak; M Tare; K P Conrad; L J Parry
Journal:  Br J Pharmacol       Date:  2016-09-30       Impact factor: 8.739

4.  Differential effects of relaxin deficiency on vascular aging in arteries of male mice.

Authors:  Maria Jelinic; Marianne Tare; Kirk P Conrad; Laura J Parry
Journal:  Age (Dordr)       Date:  2015-06-25

5.  GPCRs as potential therapeutic targets in preeclampsia.

Authors:  Jt McGuane; Kp Conrad
Journal:  Drug Discov Today Dis Models       Date:  2012-07-12

6.  Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts.

Authors:  Ashish Parikh; Divyang Patel; Charles F McTiernan; Wenyu Xiang; Jamie Haney; Lei Yang; Bo Lin; Aaron D Kaplan; Glenna C L Bett; Randall L Rasmusson; Sanjeev G Shroff; David Schwartzman; Guy Salama
Journal:  Circ Res       Date:  2013-06-07       Impact factor: 17.367

7.  Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice.

Authors:  Mark S Segal; Laura Sautina; Shiyu Li; YanPeng Diao; Alexander I Agoulnik; Jennifer Kielczewski; Jonathan T McGuane; Maria B Grant; Kirk P Conrad
Journal:  Blood       Date:  2011-10-25       Impact factor: 22.113

Review 8.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

9.  Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment.

Authors:  Maria Jelinic; Chen-Huei Leo; Emiel D Post Uiterweer; Shaun L Sandow; Jonathan H Gooi; Mary E Wlodek; Kirk P Conrad; Helena Parkington; Marianne Tare; Laura J Parry
Journal:  FASEB J       Date:  2013-09-13       Impact factor: 5.191

Review 10.  G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention.

Authors:  Kirk P Conrad
Journal:  Hum Reprod Update       Date:  2016-07-06       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.